Literature DB >> 11174067

Increased cell surface expression of receptors for transforming growth factor-beta on osteoblasts from patients with Osteogenesis imperfecta.

J Gebken1, R Brenner, A Feydt, H Notbohm, J Brinckmann, P K Müller, B Bätge.   

Abstract

Osteogenesis imperfecta (OI) is a heritable connective tissue disorder usually characterized by either a reduction in the production of normal collagen I or the synthesis of abnormal collagen. The variability in the clinical phenotype is not in each case sufficiently explained by the underlying mutation in the collagen I genes. Also, biochemical differences between mutant collagen from different tissues suggest additional regulatory mechanisms possibly involved in matrix deposition and maturation, two processes in which transforming growth factor-beta (TGF-beta) plays an important role. We, therefore, studied the cell surface expression and functional properties of TGF-beta receptors I, II and III on osteoblasts from a group of OI patients compared to healthy controls. Receptor number and affinity were determined by Scatchard analysis of binding data and TGF-beta receptor II gene expression was assessed by RT-PCR. Ligand-induced downregulation of TGF-beta receptors was analyzed to demonstrate the dynamic response to exogenous stimuli. All experiments were performed in parallel in human osteoblastic cells from OI patients and from age-matched controls. TGF-beta receptors I, II and III (betaglycan) were present on osteoblasts from both healthy donors and OI patients. The receptor numbers were significantly higher (29,000 per cell) on OI osteoblasts than on age-matched control osteoblasts (12,000 per cell) in spite of similar steady state levels for TGF-beta receptor II mRNA in OI and control cells. Furthermore, receptor affinity was not significantly different in OI osteoblasts (181 vs. 177 nM(-1)), and the receptor number did not depend on the culture substrate. With respect to dynamic adaption, ligand-induced downregulation of TGF-beta receptors was reduced in OI osteoblasts. In conclusion, the human osteoblastic cells from patients with OI investigated all have an elevated number of cell surface receptors for TGF-beta, without any evidence for a transcriptional regulation of TGF-beta receptor II. On the functional level, there is some evidence for an impaired adaptive behavior of receptor presentation, whereas receptor affinity is unchanged. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11174067     DOI: 10.1159/000055910

Source DB:  PubMed          Journal:  Pathobiology        ISSN: 1015-2008            Impact factor:   4.342


  4 in total

Review 1.  A look behind the scenes: the risk and pathogenesis of primary osteoporosis.

Authors:  Gretl Hendrickx; Eveline Boudin; Wim Van Hul
Journal:  Nat Rev Rheumatol       Date:  2015-04-21       Impact factor: 20.543

2.  Circulating TGF-β Pathway in Osteogenesis Imperfecta Pediatric Patients Subjected to MSCs-Based Cell Therapy.

Authors:  Arantza Infante; Leire Cabodevilla; Blanca Gener; Clara I Rodríguez
Journal:  Front Cell Dev Biol       Date:  2022-02-09

3.  Long Noncoding RNA Zinc Finger Antisense 1 Affects Glucocorticoid-Induced Osteonecrosis of the Femoral Head by Performing as a ceRNA for MicroRNA-124-3p and Accelerating Transforming Growth Factor Type III Receptor.

Authors:  Xiao Yong Lan; YiPin Xiong; HaiPing Ma; LingFeng Zou; Zhen Yuan; YuHong Xiao
Journal:  Comput Math Methods Med       Date:  2022-07-18       Impact factor: 2.809

4.  Role of TGF-β in a mouse model of high turnover renal osteodystrophy.

Authors:  Shiguang Liu; Wenping Song; Joseph H Boulanger; Wen Tang; Yves Sabbagh; Brian Kelley; Russell Gotschall; Susan Ryan; Lucy Phillips; Katie Malley; Xiaohong Cao; Tai-He Xia; Gehua Zhen; Xu Cao; Hong Ling; Paul C Dechow; Teresita M Bellido; Steven R Ledbetter; Susan C Schiavi
Journal:  J Bone Miner Res       Date:  2014       Impact factor: 6.741

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.